Dong-A Progresses In Diabetes With Lat Am Deal, New Study

With the global diabetes treatment market expected to show continued growth, South Korea's Dong-A ST is making progress in the sector by signing an additional licensing out contract for its new drug and successfully completing a Phase II U.S. study with a potential diabetic neuropathy therapy.